FCMV

Foresite Capital Management VI Portfolio holdings

AUM $183M

This Quarter Return

-15.51%

1 Year Return

–

3 Year Return

–

5 Year Return

–

10 Year Return

–

AUM

$183M

AUM Growth

-$41.9M (-19%)

Cap. Flow

–

Cap. Flow % of AUM

–

Top 10 Holdings %Top 10 Hldgs %

93.59%

Holding

New

–

Increased

–

Reduced

–

Closed

–

No buys this quarter

No sells this quarter

Healthcare

100%

#	Name	Market Value	Portfolio Weight	Shares or Principal	Shares Change %	Capital Flow
1	1 CG Oncology CGON $1.99B	$54.4M	29.8%	2,221,474	–	–
2	ALMS 2 Alumis Inc. Common Stock ALMS $400M	$25.8M	14.14%	4,202,670	–	–
3	CNTA 3 Centessa Pharmaceuticals CNTA $2.06B	$18M	9.87%	1,253,379	–	–
4	4 RAPT Therapeutics RAPT $220M	$15.3M	8.35%	12,500,000	–	–
5	5 Akero Therapeutics AKRO $4.03B	$14.8M	8.09%	365,000	–	–
6	6 Edgewise Therapeutics EWTX $1.49B	$12.9M	7.05%	585,000	–	–
7	BCAX 7 Bicara Therapeutics Inc. Common Stock BCAX $641M	$12.4M	6.78%	950,000	–	–
8	8 Structure Therapeutics GPCR $1.03B	$7.27M	3.98%	420,000	–	–
9	9 Allogene Therapeutics ALLO $328M	$5.03M	2.76%	3,448,275	–	–
10	10 Corvus Pharmaceuticals CRVS $363M	$5.03M	2.75%	1,581,233	–	–
11	11 Cullinan Oncology CGEM $483M	$4.8M	2.63%	634,558	–	–
12	12 Kymera Therapeutics KYMR $3.21B	$4.01M	2.19%	146,332	–	–
13	13 CASI Pharmaceuticals CASI $22.9M	$2.87M	1.57%	1,329,383	–	–
14	14 Viridian Therapeutics VRDN $1.41B	$26.6K	0.01%	1,974	–	–